drugset
drugset / Trial / NCT06504199

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

NCT06504199 ↗

Phase 2 Active not recruiting 39 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This study aims to preliminarily explore the efficacy and safety of the combination of Obinutuzumab and Zanubrutinib plus Lenalidomide (ZGR) followed by a short cycle of cytarabine and Obinutuzumab in the induction treatment of newly diagnosed mantle cell lymphoma (MCL) . The investigators propose ZGR followed by a short cycle of Obinutuzumab and cytarabine could be an effective first-line treatment for MCL.

Timeline

Start
2024-07-18
Primary completion
2026-12-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 500 mg/m2 Intravenous
Subject Cytarabine Small molecule 2000 mg/m2 Intravenous
Subject Lenalidomide Other / unclassified 5 mg Oral
Subject Obinutuzumab Monoclonal antibody 1000 mg Intravenous
Subject Zanubrutinib Small molecule 160 mg Oral

Indications

mantle cell lymphoma